Immune System Key Ltd.

Immune System Key Ltd. (ISK) is a privately held company that was founded in 2005 by Prof. Uziel Sandler and Dr. Yoram Devary.
It is engaged in discovery and development of innovative treatments for malignant and autoimmune diseases with strong unmet needs. ISK’s assets are based on novel human secreted peptides, which were discovered by the founders. ISK’s lead compound is NerofeTM. NerofeTM was granted by the FDA with orphan drug status for AML treatment and currently is in phase IIa development stage. The company holds 3 worldwide patents on the molecule and applications.

LATEST NEWS

Dr. Devary: Transforming “Cold Tumors” into “Hot Tumors”: Nerofe and DOX Synergy against KRAS Mutations

26 Oct|Comments Off on Dr. Devary: Transforming “Cold Tumors” into “Hot Tumors”: Nerofe and DOX Synergy against KRAS Mutations

  • combined_seal

Second FDA approved clinical trial in patients with pancreatic cancer and metastatic colorectal

18 Dec|Comments Off on Second FDA approved clinical trial in patients with pancreatic cancer and metastatic colorectal

ISK is excited to report the official opening of its second FDA approved clinical trial in the US in patients with pancreatic cancer and metastatic colorectal cancer at Georgetown University in Washington, D.C.

IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track

29 Nov|Comments Off on IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track

Following FDA approval to open our trial at Georgetown University in Washington DC, we received final IRB approval to open the trial in Georgetown University for the treatment of mtKRAS tumors from GI track

New Nerofe Formulation for treatment of Stage 4 squamous cell lung cancer

29 Nov|Comments Off on New Nerofe Formulation for treatment of Stage 4 squamous cell lung cancer

Using a new formulation of Nerofe, treating a patient with Stage 4 squamous cell lung cancer (positive for ST2), caused the complete disappearance of some tumors and a decrease in the size of other tumors. Increase in hepatic function.

New Nerofe Formulation for treatment of adenocarcinoma in the anus with metastasis in the peritoneum

29 Nov|Comments Off on New Nerofe Formulation for treatment of adenocarcinoma in the anus with metastasis in the peritoneum

Using a new formulation of Nerofe on a patient (positive for ST2) with adenocarcinoma in the anus and two metastasis in the peritoneum caused the complete disappearance of tumors.

  • georgetown university

ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC

23 Oct|Comments Off on ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC

ISK Ltd received FDA approval to start phase1/1b trial for treatment of GI tract mtKRAS tumors patients at Georgetown University at Washington DC